Skip to content
Companies

Stipple Bio

Cancer drugs aimed at tumor-specific cell surface markers

Raised to date

$65.1M

of $100.2M offered across 1 Form D filing

Still open
$35.1M
Investors
15
Last filed
Apr 6, 2026

About

Stipple Bio is a Cambridge, Massachusetts precision oncology company founded in 2022 that develops cancer therapeutics targeting tumor-specific cell surface epitopes. Its Pointillist platform maps thousands of subtle molecular differences on cell surfaces to identify epitopes unique to tumors rather than relying on broadly expressed surface proteins. The lead candidate, STP-100, is an antibody drug conjugate built on tumor-specific binders and is expected to enter clinical studies in early 2027. The company emerged from stealth in April 2026 with a $100 million Series A co-led by RA Capital, a16z Bio+Health and Nextech Invest.

Targets tumor-specific 'epitomics' — precise protein surface features unique to cancer cells — instead of tumor-specific gene expression, aiming to widen the therapeutic index by avoiding on-target/off-tumor toxicity. The platform is modality-agnostic, so discovered epitopes can be carried into formats beyond antibodies.

Funding

  • EquityFiled Apr 6, 2026Form D
    $65.1M/ $100.2M

Product

Pointillist platform

Drug discovery platform

A discovery platform that systematically maps cell surface epitopes at high resolution to reveal differences unique to tumor cells, then generates binders against those tumor-specific epitopes for therapeutic development.

  • Epitope-resolution cellular profiling and target discovery
  • Maps thousands of molecular points to find tumor-specific surface differences
  • Modality-agnostic — not limited to antibody formats

Built for

Cancer patients, reached through clinical development and biopharma partnerships

People on file